Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.50 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4915846 | 0.92 | CHRM2 (0.50) | MEN1KMT2AOPRM1CHRM2CHRM3 | |
| SCHEMBL4913671 | 0.92 | HRH3 (0.54) | MEN1KMT2AOPRM1CHRM2PPARG | |
| SCHEMBL4927352 | 0.92 | MEN1 (0.56) | MEN1KMT2AOPRM1CHRM2CHRM3 | |
| SCHEMBL4924870 | 0.92 | MEN1 (0.56) | MEN1KMT2AOPRM1CHRM2CHRM3 | |
| SCHEMBL4916485 | 0.92 | HRH3 (0.54) | MEN1KMT2AOPRM1CHRM2PPARG | |
| SCHEMBL4921884 | 0.91 | CXCR4 (0.52) | MEN1KMT2AOPRM1CHRM3ALDH1A1 | |
| SCHEMBL4921716 | 0.91 | TSHR (0.55) | MEN1KMT2AOPRM1PPARGEPHX2 | |
| SCHEMBL4923919 | 0.90 | CHRM3 (0.48) | MEN1KMT2AOPRM1CHRM3ACKR3 | |
| SCHEMBL4927750 | 0.89 | ACKR3 (0.58) | MEN1KMT2ACHRM3ALDH1A1ACKR3 | |
| SCHEMBL4921420 | 0.88 | HRH3 (0.50) | MEN1KMT2AOPRM1CHRM2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | CCR1, CCR3, CCR2 | MEN1 2193/4885KMT2A 3990/4885OPRM1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.